	Application Number		10715055	
INFORMATION BIGGI COURT	Filing Date		2003-11-17	
INFORMATION DISCLOSURE	First Named Inventor Gera		ald Cagle	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1618	
(not ion dubiniosion unual or of it inco,	Examiner Name Fay,		y, Zohreh A.	
	Attorney Docket Number		007109.00001	

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Oate	Name of Pate of cited Docu	entee or Applicant ment	Releva	,Columns,Lines wher ant Passages or Rele s Appear	
/ZF/	1	6716830		2004-04	4-06	Cagle et al.				
/ZF/	2	6395746	B1	2002-0	5-28	Cagle et al.				
/ZF/	3	6740664	B2	2004-0	5-25	Cagle et al.				
If you wis	If you wish to add additional U.S. Patent citation information please click the Add button. Add									
			U.S.P	ATENT	APPLIC	CATION PUBI	LICATIONS		Remove	
Examiner Initial* Cite No Publication Number Kind Code ¹ Date Name of Patentee or Applicant of cited Document Pages, Columns, Lines of Code ¹ Code ¹ Code ¹ Date Publication Number Figures Appear						ant Passages or Rele				
	1									
If you wis	h to ac	⊔ dd additional U.S. Publis	shed Ap	plication	citation	ı n information p	lease click the Add	d button	ı. Add	
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patented Applicant of cited Document	/ 1	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	. _{T5}
	1									

(Not for submission under 37 CFR 1.99)

Application Number		10715055
Filing Date		2003-11-17
First Named Inventor Geral		ld Cagle
Art Unit		1618
Examiner Name Fay, 2		Zohreh A.
Attorney Docket Number		007109.00001

If you	wish 1	to ad	d additional Foreign Patent Document citation information please click the Add button Add				
NON-PATENT LITERATURE DOCUMENTS Remove							
Exami Initials	Examiner Cite (hook magazine journal serial symposium catalog etc) date nages(s) volume issue number(s)			T 5			
<i>[</i>	/ZF/ 1 Communication of a Notice of Opposition (from EP Patent Office) dated 8/23/04, Opposition against EP Patent 1117401						
000000000000000000000000000000000000000	Declaration of David W. Stroman, Ph.D., Opposition against EP Patent 1117401		Declaration of David W. Stroman, Ph.D., Opposition against EP Patent 1117401				
30.00.00.00.00.00.00.00.00.00.00.00.00.0	3	3	Communication dated 6/28/2005 from European Patent Office regarding Opposition against EP Patent 1117401				
000000000000000000000000000000000000000	4	4 Summons to attend oral proceedings in Opposition against EP Patent 1117401					
***************************************	Ę	5	Communication dated 7/12/2006 from European Patent Office regarding Opposition against EP Patent 1117401				
200000000000000000000000000000000000000	Notification dated 7/14/06 from European Patent Office regarding Opposition against EP Patent 1117401, which includes a letter from the opponent dated 7/11/06						
***************************************	7	7	Letter from opponent dated 7/28/06 regarding Opposition against EP Patent 1117401				
000000000000000000000000000000000000000	3	8	Complaint filed 4/5/06 in Bayer Healtchare AG, Alcon, Inc., and Alcon Manufacturing Ltd. v. Teva Pharmaceuticals, USA, Inc. (C.A. No. 06-234)				
Y	ę	9	Letter from TEVA to Bayer Healthcare and Bayer Healthcare AG dated 2/21/06 regarding Patent Certification Notice - U.S. Patents 4,990,517; 5607,942; and 6,716,830				

(Not for submission under 37 CFR 1.99)

Application Number		10715055	
Filing Date		2003-11-17	
First Named Inventor Geral		ld Cagle	
Art Unit		1618	
Examiner Name Fay,		Zohreh A.	
Attorney Docket Number		007109.00001	

/ZF/	10	Answer and Defenses of Defendant Teva Pharmaceuticals USA, Inc. dated 4/28/06 Bayer Healtchare AG, Alcon, In and Alcon Manufacturing Ltd. v. Teva Pharmaceuticals, USA, Inc. (CA NO. 06-234 (SLR))						
1222-1222-1222-1222-1222-1222-1222-122	11	"Survey of Ophthalmology, Vol. 50, Supplement 1, November 2005						
000000000000000000000000000000000000000	12	Arch Ophthalmol /Vol. 123, Sept. 2005, pages 12	ulmol /Vol. 123, Sept. 2005, pages 1282-1283					
***************************************	13	Ophthalmology, Vol. 112, Number 11, November 2005, pages 1992-1996						
000000000000000000000000000000000000000	14	Ophthalmology, Vol. 113, Number 6, June 2006, pages 955-959						
	15	Survey of Ophthalmology, Vol. 50, Supplement 1, November 2005, pages 55-63						
000000000000000000000000000000000000000	16	Current Medical Research and Opinion, Vol. 21, No. 1, 2005, pages 93-94						
000000000000000000000000000000000000000	17	Ophthalmology, Vol. 112, No. 3, March 2005, pag	res 466-469					
18 Who Drug Information, Vol. 11, No. 4, 1997 pages 2		Who Drug Information, Vol. 11, No. 4, 1997 page	s 265-66 and 79					
If you wish to add additional non-patent literature document citation information please click the Add button Add								
	EXAMINER SIGNATURE							
Examine	er Signa	/Zohreh Fay/ (09/16/2009)	Date Considered					
			ation is in conformance with MPEP 609. Draw line through a by of this form with next communication to applicant.					

(Not for submission under 37 CFR 1.99)

Application Number		10715055	
Filing Date		2003-11-17	
First Named Inventor	Gera	d Cagle	
Art Unit		1618	
Examiner Name Fay,		Zohreh A.	
Attorney Docket Number		007109.00001	

¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

(Not for submission under 37 CFR 1.99)

Application Number		10715055	
Filing Date		2003-11-17	
First Named Inventor Geral		ld Cagle	
Art Unit		1618	
Examiner Name Fay,		Zohreh A.	
Attorney Docket Number		007109.00001	

	CERTIFICATION STATEMENT						
Plea	Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):						
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).						
OR	:						
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).						
	See attached cer	rtification statement.					
	Fee set forth in 3	7 CFR 1.17 (p) has been submitted herewit	h.				
✓	None						
		SIGNA	TURE				
	ignature of the ap n of the signature.	plicant or representative is required in accor	dance with CFR 1.33, 10.1	18. Please see CFR 1.4(d) for the			
Sigr	nature	/Paul M. Rivard/	Date (YYYY-MM-DD)	2006-08-31			
Name/Print Paul M. Rivard Registration Number 43446				43446			
pub 1.14	lic which is to file o	mation is required by 37 CFR 1.97 and 1.98 (and by the USPTO to process) an application s estimated to take 1 hour to complete, included USPTO. Time will vary depending upon the	on. Confidentiality is gover uding gathering, preparing	rned by 35 U.S.C. 122 and 37 CFR and submitting the completed			

require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria**,

VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.